Bio Diagnostic Business Investment Opportunities in Singapore

The company has pioneered the first blood-based cancer detection tests capable of identifying up to 30 common cancers. - We have consistently focused on innovative solutions for early-stage cancer detection to significantly reduce cancer-related deaths. - The company employs an ingenious approach that combines cutting-edge experimental tools with the latest advancements in deep learning methodologies. - With the global rise in cancer incidence, annual cancer deaths have also increased significantly. - Most cancers are diagnosed at late stages due to the absence of early clinical symptoms, leading to poor prognosis. - Early detection of cancer can reduce mortality by up to 70%, yet no current methods accurately detect cancer at early stages. - We have leveraged this opportunity by developing a groundbreaking blood test that detects 30 cancers in both males and females. - Our product integrates molecular mapping of the physiological state with a deep learning platform to identify cancer-specific molecular signatures. - The test is a novel, non-invasive blood-based screening method capable of detecting cancers and identifying the tissue of origin from the same sample. - The 30 cancers detected represent about 90% of new cancer cases each year. - Our test has achieved an unmatched accuracy of over 98% for early-stage cancer detection. - This advancement can significantly reduce the global cancer mortality burden. - The company is in the process of commercializing the test. - The promoter have over 40+ years of experience in the industry. - Licenses include CIN, SSM and GST. We have also applied for a USFDA. We have applied to the DCGI (Drugs Controller General of India) for market approval in India. We will launch operations post the DCGI approval. - Our target audience includes hospitals in India and Singapore. - Our R&D headquarters are in Haryana, with global headquarters in Singapore. - We also maintain an office in Singapore with dedicated staff.

The company has pioneered the first blood-based cancer detection tests capable of identifying up to 30 common cancers. - We have consistently focused on innovative solutions for early-stage cancer detection to significantly reduce cancer-related deaths. - The company employs an ingenious approach that combines cutting-edge experimental tools with the latest advancements in deep learning methodologies. - With the global rise in cancer incidence, annual cancer deaths have also increased significantly. - Most cancers are diagnosed at late stages due to the absence of early clinical symptoms, leading to poor prognosis. - Early detection of cancer can reduce mortality by up to 70%, yet no current methods accurately detect cancer at early stages. - We have leveraged this opportunity by developing a groundbreaking blood test that detects 30 cancers in both males and females. - Our product integrates molecular mapping of the physiological state with a deep learning platform to identify cancer-specific molecular signatures. - The test is a novel, non-invasive blood-based screening method capable of detecting cancers and identifying the tissue of origin from the same sample. - The 30 cancers detected represent about 90% of new cancer cases each year. - Our test has achieved an unmatched accuracy of over 98% for early-stage cancer detection. - This advancement can significantly reduce the global cancer mortality burden. - The company is in the process of commercializing the test. - The promoter have over 40+ years of experience in the industry. - Licenses include CIN, SSM and GST. We have also applied for a USFDA. We have applied to the DCGI (Drugs Controller General of India) for market approval in India. We will launch operations post the DCGI approval. - Our target audience includes hospitals in India and Singapore. - Our R&D headquarters are in Haryana, with global headquarters in Singapore. - We also maintain an office in Singapore with dedicated staff.